Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ClinicalTrials.gov |
Last refreshed on:
|
19 February 2015 |
Main ID: |
NCT02188654 |
Date of registration:
|
04/07/2014 |
Prospective Registration:
|
No |
Primary sponsor: |
|
Public title:
|
Metformin in Psoriatic Arthritis
|
Scientific title:
|
Metformin: A Valid Add-On Drug in the Treatment of Psoriatic Arthritis-Randomized Controlled Trial |
Date of first enrolment:
|
September 2013 |
Target sample size:
|
56 |
Recruitment status: |
Completed |
URL:
|
http://clinicaltrials.gov/show/NCT02188654 |
Study type:
|
Interventional |
Study design:
|
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
|
Phase:
|
N/A
|
|
Countries of recruitment
|
Egypt
| | | | | | | |
Contacts
|
Name:
|
Anna Abou-Raya, MD |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
University of Alexandria |
| | |
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Psoriatic arthritis patients
Exclusion Criteria:
- other inflammatory conditions
Age minimum:
18 Years
Age maximum:
N/A
Gender:
Both
|
Health Condition(s) or Problem(s) studied
|
Psoriatic Arthritis
|
Intervention(s)
|
Drug: Metformin
|
Drug: Placebo
|
Primary Outcome(s)
|
ACR20 response
[Time Frame: 24 weeks]
|
Secondary Outcome(s)
|
Psoriatic arthritis response criteria (PsARC) score
[Time Frame: 24 weeks]
|
Disability Index (HAQ-DI)
[Time Frame: 24 weeks]
|
PASI score
[Time Frame: 24 weeks]
|
Health Assessment Questionnaire
[Time Frame: 24 weeks]
|
Secondary ID(s)
|
alexmed12671416
|
Source(s) of Monetary Support
|
Please refer to primary and secondary sponsors
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|